Sept. 1, 2016
Amgen and Servier have announced that their cardiovascular collaboration advances, with the decision of Servier to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, as well in as the Commonwealth of Independent States, including Russia. The pharma companies also announced that the omecamtiv mecarbil Phase 3 development program will move forward in collaboration with Cytokinetics.
As per the terms of the agreement, Servier will make a $10 million option exercise payment, as well as future milestone and royalty payments, to Amgen. Servier will also assume a share of the development costs. The decision to advance omecamtiv mecarbil into Phase 3 was based on positive results from COSMIC-HF, a Phase 2 trial evaluating the treatment in patients with chronic heart failure
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, said: “We are very pleased to strengthen our collaboration with Servier and for the continued advancement of the novel cardiac myosin activator omecamtiv mecarbil. We are working closely with our research collaborators and regulators on the Phase 3 outcomes study for omecamtiv mecarbil and look forward to assessing the potential of this unique therapy to benefit patients with chronic heart failure worldwide.”
“Omecamtiv mecarbil is a very innovative approach to treating chronic heart failure, bringing new hope to patients suffering from this severe condition. We are pleased to collaborate with Amgen in the late stage of its clinical development for omecamtiv mecarbil,” said Emmanuel Canet, M.D., Ph.D., executive vice-president of Research and Development at Servier.Amgen and Servier Extend Omecamtiv Mecarbil Collaboration in Chronic Heart Failurelast edit: 2016-09-13T17:07:19+00:00da